{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:02:33Z","timestamp":1771045353913,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resmer.2024.101102","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:55:35Z","timestamp":1710492935000},"page":"101102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effect of elexacaftor-tezacaftor-ivacaftor on lipid parameters in adults with cystic fibrosis: A single centre preliminary report"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9693","authenticated-orcid":false,"given":"Ronan","family":"Docherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Folganan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.resmer.2024.101102_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.resmer.2024.101102_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.resmer.2024.101102_bib0003","article-title":"A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.resmer.2024.101102_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"1","author":"Petersen","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.resmer.2024.101102_bib0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/01.STR.25.4.814","article-title":"Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk","volume":"25","author":"Benfante","year":"1994","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.resmer.2024.101102_bib0006","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.21037\/jtd.2018.06.141","article-title":"Lung transplantation: indications and contraindications","volume":"10","author":"Weill","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resmer.2024.101102_bib0007","unstructured":"Cystic Fibrosis Trust (2022). Management of cystic fibrosis diabetes Second edition. 2022. [Online] https:\/\/www.cysticfibrosis.org.uk\/. Available at:https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-12\/CF%20Diabetes%20Consensus%20FINAL_0.pdf [Accessed 28 Feb. 2024]."},{"key":"10.1016\/j.resmer.2024.101102_bib0008","unstructured":"Cystic Fibrosis Trust (2016). Nutritional Management of Cystic Fibrosis. [online] https:\/\/www.cysticfibrosis.org.uk\/. Available at:https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/Nutritional%20Management%20of%20cystic%20fibrosis%20Sep%2016.pdf [Accessed 1 Jul. 2023]."},{"issue":"8","key":"10.1016\/j.resmer.2024.101102_bib0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Internl Med"},{"issue":"7","key":"10.1016\/j.resmer.2024.101102_bib0010","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.21037\/jtd.2018.06.141","article-title":"Lung transplantation: indications and contraindications","volume":"10","author":"Weill","year":"2018","journal-title":"J Thorac Dis,"},{"key":"10.1016\/j.resmer.2024.101102_bib0011","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"issue":"1","key":"10.1016\/j.resmer.2024.101102_bib0012","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.diabres.2004.05.006","article-title":"Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III","volume":"67","author":"Lee","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.resmer.2024.101102_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/ejvs.2001.1321","article-title":"Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume","volume":"21","author":"Gr\u00f8nholdt","year":"2001","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.resmer.2024.101102_bib0014","unstructured":"Cystic Fibrosis Trust (2020). UK Cystic Fibrosis Registry Annual Data Report 2019 UK Cystic Fibrosis Registry 2019 Annual Data Report Acknowledgements. [online] Available at: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/2019%20Registry%20Annual%20Data%20report_Sep%202020.pdf [Accessed 11 Nov. 2022]."}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041224000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041224000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T08:03:11Z","timestamp":1734163391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041224000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":14,"alternative-id":["S2590041224000187"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2024.101102","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of elexacaftor-tezacaftor-ivacaftor on lipid parameters in adults with cystic fibrosis: A single centre preliminary report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2024.101102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101102"}}